3066 Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study. (September 2015) - Joerger, M.; Von Pawel, J.; Kraff, S.; Fischer, J.R.; Gauler, T.; Mueller, L.; Reinmuth, N.; Reck, M.; Kimmich, M.; Frank, M.; Kopp, H.G.; Behringer, D.; et al.